Patent ID: 7842661

Claim:
A pharmaceutical composition comprising about 0.1 mg/ml to about 1 mg/ml of an erythropoietin peptide and a buffer, the composition having a pH from 5.5 to 6.5, wherein the erythropoietin peptide comprises a glycosyl linking group attached to an amino acid residue or a glycosyl residue of said peptide, wherein the amino acid residue is selected from the group consisting of serine, threonine, and asparagine, said glycosyl linking group comprising a modified sialyl residue having the formula: wherein R 2 is H, CH 2 OR 7 , COOR 7 , COO − or OR 7 wherein R 7 represents H, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl; R 3 and R 4 are members independently selected from H, substituted or unsubstituted alkyl, OR 8 , NHC(O)R 9 wherein R 8 and R 9 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl or sialic acid; s is an integer from 1 to 20; f is an integer from 1 to 2500; and Q is a member selected from H and substituted or unsubstituted C 1 -C 6 alkyl; and wherein the buffer comprises one or more members selected from the group consisting of acetate, carbonate, citrate, glycinate, histidine, lactate, maleate, phosphate, succinate, tartrate, and tris; and the pharmaceutical composition shows no detectable level of aggregation of the erythropoietin peptide as measured by SEC-HPLC after three months at a temperature of 5° C. or lower.